Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Tukysa

TUKYSA 50 mg film-coated tablets TUKYSA 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-145571 · Präparat HOS-099373

CYP3A substrates Tucatinib is a strong CYP3A inhibitor. A clinical drug interaction study found that co-administration of tucatinib with midazolam (a sensitive CYP3A substrate) resulted in an increase in midazolam concentrations (3.0-fold Cmax (90% CI: 2.6, 3.4) and 5.7-fold AUC (90% CI: 5.0, 6.5)). Co-administration of tucatinib with sensitive CYP3A substrates such as alfentanil, avanafil, buspirone, darifenacin, darunavir, ebastine, everolimus, ibrutinib, lomitapide, lovastatin, midazolam, naloxegol, saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir, triazolam, and vardenafil may increase their systemic exposures which may increase the toxicity associated with a CYP3A substrate. Concomitant use of tucatinib with CYP3A substrates, when minimal concentration changes may lead to serious or life-threatening toxicities, should be avoided. If concomitant use is unavoidable, the CYP3A substrate dosage should be decreased in accordance with the concomitant medicinal product SmPC.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) lovastatin (HOS-086157) lomitapide (HOS-086160) ebastine (HOS-132877) simvastatin (HOS-086158) avanafil (HOS-086161) naloxegol (HOS-109428) lead (HOS-085592) saquinavir (HOS-084522) tacrolimus (HOS-085202) darunavir (HOS-086181) everolimus (HOS-086310) buspirone (HOS-086325) sirolimus (HOS-085172) darifenacin (HOS-113065) triazolam (HOS-086168) tipranavir (HOS-086184) ibrutinib (HOS-086226) midazolam (HOS-086167) vardenafil (HOS-086163)